Zolinza (vorinostat, MK0683)
| Brand Name: | Zolinza |
| Generic Name: | vorinostat |
| Code Name: | MK0683 |
| Company: | Merck Pharmaceuticals |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Zolinza (news articles), which is an approved drug for cutaneous T-cell lymphoma, is also being studied in combination with Velcade (bortezomib) for treatment of multiple myeloma. Zolinza is a histone deacetylase (HDAC) inhibitor, which modifies the way that cancer cell DNA is converted into protein. HDAC controls DNA unfolding in the first step of protein production, and drugs that inhibit HDAC, like Zolinza, increase the production of protein. HDAC inhibitors are used in cancer treatment to increase the production of proteins that slow cell division, repair DNA mistakes, and control cell death. Researchers hope that this should help the body prevent cells from multiplying out of control and becoming cancerous.
Clinical Trials:
For a list of clinical trials studying Zolinza for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official Web site for Zolinza: http://www.zolinza.com/
Related Articles:
- Getting To Know: TNB-383B
- Getting To Know: Tiragolumab
- Lather, Rinse, Repeat: Will It Work With BCMA-Targeted Therapies For Multiple Myeloma?
- U.S. FDA Okays First Clinical Trial Of An Allogeneic CAR T-Cell Therapy For Multiple Myeloma
- Common Measures Of Heart And Blood Vessel Health May Predict Risk Of Heart-Related Side Effects During Treatment With Kyprolis